Mohammad Shoari, MD
Neurology · Salt Lake City, UTNPI 1740483395
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Medtronic at 33.9% of the total. 2025 is the largest year on record at $3,739, 7.6 times the $493 reported in 2019.
Across 122 payments — averaging $48.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Neuropace, Inc.$2K
- Livanova USA, Inc.$1K
- AbbVie$347
- Teva Pharmaceuticals USA, Inc.$216
- Argenx US, Inc.$121
- plus $643 from 15 others
What the payments were for
- Travel & lodging$2,62944%
- Food & beverage$3,30756%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 20 | $2,017 |
| Neuropace, Inc. | 6 | $1,546 |
| Livanova USA, Inc. | 11 | $1,065 |
| AbbVie(2 entities) | 19 | $347 |
| Teva Pharmaceuticals USA, Inc. | 36 | $216 |
| Argenx US, Inc. | 6 | $121 |
| Acorda Therapeutics, Inc | 1 | $110 |
| UCB, Inc. | 3 | $86 |
| Acadia Pharmaceuticals Inc | 3 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $59 |
| Boston Scientific | 1 | $58 |
| MDD US Operations, LLC | 1 | $48 |
| Bristol Myers Squibb | 1 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Lilly USA, LLC | 2 | $30 |
| Merz Pharmaceuticals, LLC | 1 | $29 |
| Genentech USA, Inc. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Greenwich Biosciences, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,955 in reported general payments places this provider in the 70th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 24 | $437,549 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 37 | $395,278 |
| IngrezzaValbenazine Tosylate | 12 | $184,465 |
| BriviactBrivaracetam | 23 | $35,282 |
| BotoxOnabotulinumtoxina | 21 | $28,097 |
| UbrelvyUbrogepant | 23 | $23,406 |
| RytaryCarbidopa/Levodopa | 13 | $22,549 |
| QuliptaAtogepant | 15 | $15,945 |
| Lacosamide | 85 | $10,007 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,588 |
| EliquisApixaban | 13 | $8,712 |
| Gabapentin | 291 | $4,150 |
| Droxidopa | 14 | $3,819 |
| Pregabalin | 101 | $2,941 |
| Carbamazepine ErCarbamazepine | 18 | $2,115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart | $121 | $437,54924 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $347 | $67,44959 claims |
| UCB, Inc.Briviact | $86 | $35,28223 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $31 | $24,09636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 157 neurology providers in Utah.
Other neurology in Salt Lake City
- Timothy WestSalt Lake City$856K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Albert SmithSalt Lake City$122K
- John FoleySalt Lake City$99K
- Kevin BrennanSalt Lake City$81K
- Lucy DewittSalt Lake City$81K
- Nicholas JohnsonSalt Lake City$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.